Business context and reporting period
Entity mismatch: The request identifies Lipocine Inc., but the supplied filing is for Marathon Bar Corp. This summary reflects the filing text, not Lipocine. Marathon Bar filed this unaudited Form 10-Q for the quarter ended March 31, 2012. The Delaware development-stage company planned to import and sell healthy energy snack bars, but had not begun operations or generated revenue. The filing identifies it as a shell company.
Financial results and liquidity
- Revenue: $0 for the quarter and since inception.
- Expenses and earnings: General and administrative expense and net loss were each $4,812 for the quarter, versus no reported expense or loss in the comparable 2011 quarter. The filing reports loss per share of $0.00, with 3,000,000 weighted-average shares.
- Cash flow: Cash used in operating activities was $5,052; there was no investing or financing cash flow during the quarter. Cash declined from $22,943 at year-end to $17,891 at March 31.
- Balance sheet: Total assets were $27,391, including $17,891 cash and $9,500 deferred offering costs. Current liabilities were $7,365, including $7,127 accounts payable and accrued expenses and $238 due to shareholders. Stockholders’ equity was $20,026. No interest-bearing debt is reported; the $238 related-party advance is unsecured, non-interest-bearing, and due on demand.
- Margins: Not meaningful because the company had no revenue.
Changes and notable items
Quarterly G&A expense rose to $4,812 from zero in the prior-year quarter, mainly reflecting S-1 filing, audit, and legal costs. The accumulated development-stage deficit increased from $5,162 at December 31, 2011 to $9,974 at March 31, 2012. On April 2, 2012, the company accepted subscriptions for 500,000 restricted shares for $50,000. The balance sheet reports 3,000,000 shares outstanding at quarter-end; the cover reports 3,500,000 issued and outstanding as of May 8, 2012.
Outlook, risks, and contingencies
Management stated that the company needed additional capital to execute its plan and that significant revenue was not expected before financing and implementation. Its proposed plan depended on market and regulatory research, developing its concept and website, and identifying suppliers and partners; it did not plan to manufacture the bars itself. Management described a target of becoming functional within 12 months after raising capital and believed successful financing could allow sales revenue within the following 12 months, but provided no revenue or earnings guidance.
The filing states that the company’s cash resources were insufficient for its current business plan and that the absence of revenue and need for financing raised substantial doubt about its ability to continue as a going concern. The sole officer and director said he might provide unsecured loans for reporting costs if other proceeds were unavailable, but there was no contract or written commitment. The intended S-1 self-directed offering sought to sell up to 1,500,000 shares at $0.10 each, for up to $150,000; the filing reports $9,500 in deferred offering costs at quarter-end. Management reported no material legal proceedings, no material off-balance-sheet arrangements, and effective disclosure controls. No market-risk disclosure was applicable.
Investor verification points
- Confirm the issuer identity: the supplied document is Marathon Bar Corp., not Lipocine Inc.
- Check the status and terms of the S-1 offering, including the April 2 subscription and subsequent proceeds received.
- Assess the going-concern warning, available cash, and whether financing or the director’s informal funding indication materialized.
- Reconcile the MD&A statement that the January–March period’s net loss was $5,052 with the financial statements’ reported net loss of $4,812; $5,052 is reported as operating cash used.
- Verify the share count and any issuance between March 31 and May 8, 2012.